Immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced nasopharyngeal cancer (stage III or IVA, but not certain subtypes).
- You are in good physical condition (able to care for yourself and up and about more than half of your waking hours).
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
- You do not have another active cancer, serious heart or lung disease, active hepatitis, tuberculosis, or a weak immune system.
- You have not had prior chemotherapy, radiation, or surgery for your nasopharyngeal or neck cancer (except a biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, radiation, and omega-3 supplements for people with locally advanced nasopharyngeal cancer that hasn't spread. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.